NCT03593655View on ClinicalTrials.gov

Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

PHASE2CompletedINTERVENTIONAL

Enrollment

247

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

September 9, 2021

Study Completion Date

September 9, 2021

Conditions

HIV Infections

Interventions

DEVICE

Dapivirine vaginal ring

Vaginal ring containing 25 mg of dapivirine

DRUG

FTC/TDF

Tablet containing 200 mg FTC/300 mg TDF

Trial Locations (4)

2038

Wits Reproductive Health and HIV Institute CRS (WRHI CRS), Johannesburg

7750

Emavundleni CRS, Cape Town

Unknown

MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala

Spilhaus CRS, Southerton

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03593655 - Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population | Biotech Hunter | Biotech Hunter